Development of a Bioluminescent Cell-Based Assay to ... - Promega
Development of a Bioluminescent Cell-Based Assay to ... - Promega
Development of a Bioluminescent Cell-Based Assay to ... - Promega
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Fc effec<strong>to</strong>r biological activity correlates well with<br />
antibody N-glycosylation<br />
Relative activity in reporter ADCC<br />
Rituximab and Trastuzumab:<br />
Good correlation between blended<br />
% mixes <strong>of</strong> fully N-glycosylated and<br />
deglycosylated preparations and<br />
their relative biological activity in<br />
ADCC Reporter Bioassay<br />
0.700<br />
0.600<br />
0.500<br />
0.400<br />
0.300<br />
0.200<br />
0.100<br />
0.000<br />
-0.100<br />
Confidential and Proprietary. Not for Further Disclosure.<br />
y = 0.0127x - 0.0314<br />
R² = 0.966<br />
Trastuzumab<br />
0 10 20 30 40 50 60<br />
Percent N-glycosylated sample<br />
Relative activity in reporter ADCC<br />
0.700<br />
0.600<br />
0.500<br />
0.400<br />
0.300<br />
0.200<br />
0.100<br />
0.000<br />
y = 0.0125x - 0.0095<br />
R² = 0.9926<br />
Rituximab<br />
0 10 20 30 40 50 60<br />
Percent N-glycosylated sample<br />
Small differences in Fc effec<strong>to</strong>r activity<br />
in ADCC MOA pathway are easily<br />
distinguished in the ADCC reporter<br />
bioassay<br />
24
Change language